About Lucid Diagnostics
Lucid Diagnostics is a company based in New York (United States) founded in 2018.. The company has 72 employees as of December 31, 2024. Lucid Diagnostics has completed 1 acquisition, including CapNostics. Lucid Diagnostics offers products and services including EsoGuard and EsoCheck. Lucid Diagnostics operates in a competitive market with competitors including PAVmed, Previse, Cyted, BeamLine Diagnostics and CapNostics, among others.
- Headquarter New York, United States
- Employees 72 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lucid Diagnostics Inc.
-
Annual Revenue
$4.35 M79as on Dec 31, 2024
-
Net Profit
$-45.53 M13.55as on Dec 31, 2024
-
EBITDA
$-44.88 M2.39as on Dec 31, 2024
-
Latest Funding Round
$5 M (USD), Post-IPO
Oct 18, 2023
-
Investors
-
Employee Count
72
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lucid Diagnostics
Lucid Diagnostics is a publicly listed company on the NASDAQ with ticker symbol LUCD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lucid Diagnostics
Lucid Diagnostics offers a comprehensive portfolio of products and services, including EsoGuard and EsoCheck. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
DNA test for early detection of esophageal precancer without endoscopy.
Tool for identifying esophageal precancer risks in office visits.
Unlock access to complete
Unlock access to complete
Funding Insights of Lucid Diagnostics
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $5.0M
-
First Round
First Round
(22 Mar 2023)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Post-IPO - Lucid Diagnostics | Valuation |
investors |
|
| Mar, 2023 | Amount | Post-IPO - Lucid Diagnostics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Lucid Diagnostics
Lucid Diagnostics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CapNostics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
FDA-cleared swallowable device is used for non-endoscopic GI screening.
|
2013 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Lucid Diagnostics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lucid Diagnostics Comparisons
Competitors of Lucid Diagnostics
Lucid Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PAVmed, Previse, Cyted, BeamLine Diagnostics and CapNostics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of medical devices and biomarkers to detect various diseases
|
|
| domain | founded_year | HQ Location |
Cancer detection and prevention solutions are developed by Previse.
|
|
| domain | founded_year | HQ Location |
Non-endoscopic diagnostics for early gastrointestinal disease detection are developed.
|
|
| domain | founded_year | HQ Location |
Offers bedside pre-screening technology solutions for cancer detection.
|
|
| domain | founded_year | HQ Location |
FDA-cleared swallowable device is used for non-endoscopic GI screening.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lucid Diagnostics
Frequently Asked Questions about Lucid Diagnostics
When was Lucid Diagnostics founded?
Lucid Diagnostics was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Where is Lucid Diagnostics located?
Lucid Diagnostics is headquartered in New York, United States. It is registered at New York, New York, United States.
How many employees does Lucid Diagnostics have?
As of Dec 31, 2024, the latest employee count at Lucid Diagnostics is 72.
What is the annual revenue of Lucid Diagnostics?
Annual revenue of Lucid Diagnostics is $4.35M as on Dec 31, 2024.
What does Lucid Diagnostics do?
Lucid Diagnostics was founded in 2018 in New York, United States, within the medical diagnostics sector. A non-invasive testing platform is provided by the company to identify esophageal cancer biomarkers. EsoGuard is employed to detect 31 methylated DNA markers associated with Barretts esophagus. EsoCheck functions as a device for collecting targeted esophageal cells. Operations focus on advancing early detection methods for gastrointestinal conditions.
Who are the top competitors of Lucid Diagnostics?
What products or services does Lucid Diagnostics offer?
Lucid Diagnostics offers EsoGuard and EsoCheck.
Is Lucid Diagnostics publicly traded?
Yes, Lucid Diagnostics is publicly traded on NASDAQ under the ticker symbol LUCD.
How many acquisitions has Lucid Diagnostics made?
Lucid Diagnostics has made 1 acquisition, including CapNostics.
What is Lucid Diagnostics's ticker symbol?
The ticker symbol of Lucid Diagnostics is LUCD on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.